Selected article for: "potential role and SARS infection"

Author: Zamorano Cuervo, Natalia; Grandvaux, Nathalie
Title: ACE2: Evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities
  • Cord-id: c6slj9be
  • Document date: 2020_11_9
  • ID: c6slj9be
    Snippet: Pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus 19 disease (COVID-19) which presents a large spectrum of manifestations with fatal outcomes in vulnerable people over 70-years-old and with hypertension, diabetes, obesity, cardiovascular disease, COPD, and smoking status. Knowledge of the entry receptor is key to understand SARS-CoV-2 tropism, transmission and pathogenesis. Early evidence pointed to angiotensin-converting enzyme 2 (ACE2) as SARS-CoV-2 entry
    Document: Pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus 19 disease (COVID-19) which presents a large spectrum of manifestations with fatal outcomes in vulnerable people over 70-years-old and with hypertension, diabetes, obesity, cardiovascular disease, COPD, and smoking status. Knowledge of the entry receptor is key to understand SARS-CoV-2 tropism, transmission and pathogenesis. Early evidence pointed to angiotensin-converting enzyme 2 (ACE2) as SARS-CoV-2 entry receptor. Here, we provide a critical summary of the current knowledge highlighting the limitations and remaining gaps that need to be addressed to fully characterize ACE2 function in SARS-CoV-2 infection and associated pathogenesis. We also discuss ACE2 expression and potential role in the context of comorbidities associated with poor COVID-19 outcomes. Finally, we discuss the potential co-receptors/attachment factors such as neuropilins, heparan sulfate and sialic acids and the putative alternative receptors, such as CD147 and GRP78.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute lung injury: 1, 2, 3, 4
    • ace inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • ace inhibitor and adipose tissue: 1
    • ace inhibitor and lung biopsy: 1
    • ace inhibitor and lung epithelium: 1, 2
    • ace inhibitor and lung increase: 1, 2, 3
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • ace inhibitor and lung specific: 1, 2
    • ace inhibitor and lung tissue: 1, 2, 3, 4
    • ace propose and acute ards respiratory distress syndrome: 1
    • ace propose and acute respiratory syndrome: 1, 2
    • ace propose and lung injury: 1
    • acid residue and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acid residue and low expression: 1
    • acid residue and lung specific: 1
    • acid residue and lung tissue: 1
    • acinar cell and adipose tissue: 1